EGFR and non-small cell lung carcinoma: In the CEE cohort, three out of four patients with EGFRm NSCLC experienced disease progression (74%) on 1L 1G/2G EGFR TKI therapy after a median of 14 (95% CI: 12.6; 15.6) months.